Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury

• Published in: American journal of physiology. Renal physiology 2016-04, Vol.310 (8), p.F705-F716
• Main Authors: Skrypnyk, Nataliya I, Sanker, Subramaniam, Skvarca, Lauren Brilli, Novitskaya, Tatiana, Woods, Clara, Chiba, Takuto, Patel, Kevin, Goldberg, Natasha D, McDermott, Lee, Vinson, Paige N, Calcutt, M Wade, Huryn, Donna M, Vernetti, Lawrence A, Vogt, Andreas, Hukriede, Neil A, de Caestecker, Mark P
• Format: Article
• Language: English
• Subjects: Acute Kidney Injury - drug therapy; Acute Kidney Injury - pathology; Animals; Butyrates - pharmacology; Butyrates - therapeutic use; Call for Papers; Cell Proliferation - drug effects; Cell Survival - drug effects; Cells; Disease Models, Animal; Fibrosis - drug therapy; Fibrosis - pathology; Genotype & phenotype; Kidney - drug effects; Kidney - pathology; Kidney diseases; Male; Medical diagnosis; Mice; Molecules; Rodents; Sulfides - pharmacology; Sulfides - therapeutic use; Zebrafish
• ISSN: 1931-857X; 1522-1466
• DOI: 10.1152/ajprenal.00503.2015

No therapies have been shown to accelerate recovery or prevent fibrosis after acute kidney injury (AKI). In part, this is because most therapeutic candidates have to be given at the time of injury and the diagnosis of AKI is usually made too late for drugs to be efficacious. Strategies to enhance post-AKI repair represent an attractive approach to address this. Using a phenotypic screen in zebrafish, we identified 4-(phenylthio)butanoic acid (PTBA), which promotes proliferation of embryonic kidney progenitor cells (EKPCs), and the PTBA methyl ester UPHD25, which also increases postinjury repair in ischemia-reperfusion and aristolochic acid-induced AKI in mice. In these studies, a new panel of PTBA analogs was evaluated. Initial screening was performed in zebrafish EKPC assays followed by survival assays in a gentamicin-induced AKI larvae zebrafish model. Using this approach, we identified UPHD186, which in contrast to UPHD25, accelerates recovery and reduces fibrosis when administered several days after ischemia-reperfusion AKI and reduces fibrosis after unilateral ureteric obstruction in mice. UPHD25 and 186 are efficiently metabolized to the active analog PTBA in liver and kidney microsome assays, indicating both compounds may act as PTBA prodrugs in vivo. UPHD186 persists longer in the circulation than UPHD25, suggesting that sustained levels of UPHD186 may increase efficacy by acting as a reservoir for renal metabolism to PTBA. These findings validate use of zebrafish EKPC and AKI assays as a drug discovery strategy for molecules that reduce fibrosis in multiple AKI models and can be administered days after initiation of injury.